ExThera Medical

ExThera Medical ExThera Medical develops extracorporeal blood filtration devices for removing harmful substances from the bloodstream of patients.

November is Month, and ExThera Medical is committed to advancing the fight against this relentless disease.Our clinica...
11/05/2024

November is Month, and ExThera Medical is committed to advancing the fight against this relentless disease.

Our clinical trials aim to explore innovative potential therapies designed to offer new hope for patients and their families. We believe that every patient deserves better options, and we’re dedicated to finding solutions that can transform pancreatic cancer care.

Learn more: https://www.clinicaltrials.gov/study/NCT06481397

Phase I of our OSCAR I STUDY is complete!A total of five patients with metastatic Pancreatic Ductal Adenocarcinoma (PDAC...
09/25/2024

Phase I of our OSCAR I STUDY is complete!

A total of five patients with metastatic Pancreatic Ductal Adenocarcinoma (PDAC) have completed the ONCObind Procedure at OU Health Stephenson Cancer Center with no safety concerns or signals that have been observed.

Data has subsequently been submitted to the FDA for review and approval in order to proceed to the second phase of the feasibility trial (OSCAR II), with a proposal for expanding the patient population to include Metastatic Colorectal Cancer (MCRC), in addition to metastatic PDAC.

The OSCAR study is a Prospective Single-Arm Feasibility Trial to evaluate the initial safety and signals of efficacy by determining the ability of the ONCObind Procedure Hemoperfusion Filter to remove Circulating Tumor Cells (CTCs) from the blood of patients with metastatic PDAC.

Learn more: https://www.clinicaltrials.gov/study/NCT06481397

We're thrilled to announce that the first patient has been enrolled in our OSCAR I Trial at OU Health Stephenson Cancer ...
09/04/2024

We're thrilled to announce that the first patient has been enrolled in our OSCAR I Trial at OU Health Stephenson Cancer Center.

This groundbreaking study aims to evaluate the ability of the ONCObind procedure hemoperfusion filter to remove Circulating Tumor Cells (CTCs) from the blood of patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC).

As we begin this important work, we're hopeful that this innovation will pave the way for new treatment options for patients who currently face limited choices and challenging prognoses.

Learn more: https://www.clinicaltrials.gov/study/NCT06481397

Please join us this week at AKI-CRRT (CRRTonline) to learn the latest about the role of Seraph 100 for extracorporeal pa...
03/12/2024

Please join us this week at AKI-CRRT (CRRTonline) to learn the latest about the role of Seraph 100 for extracorporeal pathogen removal as a core strategy in the treatment of sepsis.

👉 Sign up as a part of your conference registration here: https://www.crrtonline.com/conference/registration/

ExThera’s commitment to quality is exemplified in these two recent certifications and demonstrates commitment to pursue ...
09/20/2023

ExThera’s commitment to quality is exemplified in these two recent certifications and demonstrates commitment to pursue global access for its Seraph® 100 Microbind® Affinity Blood Filter and OncoBind™ technologies: to provide benefit where there is significant unmet need and few existing treatment options.

Address

Martinez, CA

Telephone

+19258392060

Website

Alerts

Be the first to know and let us send you an email when ExThera Medical posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to ExThera Medical:

Shortcuts

Share

Category